Document is current
Any future updates will be listed below
-
Authors
Lampl, Christian
Seng, Elizabeth
Vincent, Maurice
Lenderking, William R.
Hoyt, Margaret
Hetherington, Lucinda
Ladd, Mary Kate
Malley, Karen
Chen, Jun
Viktrup, Lars
-
Funding
Funding for this research was provided by:
Eli Lilly and Com
- License Information
-
More Information
Article History
Received: 25 September 2024
Accepted: 25 November 2024
First Online: 18 December 2024
Declarations
:
: This study was approved by an institutional review board and conformed with International Conference on Harmonization guidelines and was conducted in accordance with the World Medical Association Declaration of Helsinki and applicable local data protection laws.
: Not applicable.
: Elizabeth Seng: research funding from the National Institutes of Health, Veterans Health Administration, Cystic Fibrosis Foundation, and the American Heart Association, as well as fees for consulting from GlaxoSmithKline, Theranica, and Abbvie.Christian Lampl: consulting fees and honoraria for lectures/ presentations from AbbVie/Allergan, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva. Principal investigator in clinical trials as the for Eli Lilly. Past-president of the European Headache Federation and associate editor for The Journal of Headache and Pain.Lars Viktrup and Margaret Hoyt are employees of Eli Lilly and Company and may own Lilly stock. Maurice Vincent was an employee of Eli Lilly and Company at the time the study was conducted and may own Lilly stock.William R. Lenderking, Mary Kate Ladd, and Karen Malley are employees of Evidera.
